Martine Paquette, Mark Trinder, Isabelle Ruel, Simon-Pierre Guay, Robert A Hegele, Jacques Genest, Liam R Brunham, Alexis Baass
{"title":"Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia.","authors":"Martine Paquette, Mark Trinder, Isabelle Ruel, Simon-Pierre Guay, Robert A Hegele, Jacques Genest, Liam R Brunham, Alexis Baass","doi":"10.1016/j.jacl.2025.01.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with familial hypercholesterolemia (FH) are at increased risk of atherosclerotic cardiovascular disease (ASCVD). However, this risk is heterogeneous, and the contribution of several clinical risk factors has been well demonstrated in this population. The proportion of the risk conferred by the accumulation of common small effect variants in coronary artery disease (CAD) susceptibility genes remains to be determined.</p><p><strong>Objective: </strong>The objective was to determine if a weighted polygenic risk score (PRS) for CAD (PRS<sub>CAD</sub>) is associated with ASCVD risk in patients with heterozygous FH (HeFH).</p><p><strong>Methods: </strong>This study included 1886 participants with HeFH from 3 independent cohorts: the FH Canada national registry, the UK Biobank, and the Montreal Clinical Research Institute FH cohort. The lifelong ASCVD risk was compared between groups using Kaplan-Meier estimates and Cox proportional hazards regression models.</p><p><strong>Results: </strong>The group with a high PRS<sub>CAD</sub> (>75th percentile) had a ∼2-fold increased risk of ASCVD compared to those with a lower PRS<sub>CAD</sub> (≤75th percentile) (HR 1.92 (1.55-2.37), P < .0001). The effect of the PRS<sub>CAD</sub> on ASCVD risk remained significant after correction for clinical risk factors (P = .0002). This association was similar between women and men (P interaction = .68), between genetic and clinical FH (P interaction = .48), between cohorts (P interaction = .39), and between the type of PRS (P interaction = .81).</p><p><strong>Conclusion: </strong>We demonstrated in the largest study to date that the use of a PRS<sub>CAD</sub> allowed us to further refine risk stratification in HeFH. Further studies are needed to evaluate the clinical value of adding the PRS<sub>CAD</sub> to current risk prediction tools.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jacl.2025.01.004","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Patients with familial hypercholesterolemia (FH) are at increased risk of atherosclerotic cardiovascular disease (ASCVD). However, this risk is heterogeneous, and the contribution of several clinical risk factors has been well demonstrated in this population. The proportion of the risk conferred by the accumulation of common small effect variants in coronary artery disease (CAD) susceptibility genes remains to be determined.
Objective: The objective was to determine if a weighted polygenic risk score (PRS) for CAD (PRSCAD) is associated with ASCVD risk in patients with heterozygous FH (HeFH).
Methods: This study included 1886 participants with HeFH from 3 independent cohorts: the FH Canada national registry, the UK Biobank, and the Montreal Clinical Research Institute FH cohort. The lifelong ASCVD risk was compared between groups using Kaplan-Meier estimates and Cox proportional hazards regression models.
Results: The group with a high PRSCAD (>75th percentile) had a ∼2-fold increased risk of ASCVD compared to those with a lower PRSCAD (≤75th percentile) (HR 1.92 (1.55-2.37), P < .0001). The effect of the PRSCAD on ASCVD risk remained significant after correction for clinical risk factors (P = .0002). This association was similar between women and men (P interaction = .68), between genetic and clinical FH (P interaction = .48), between cohorts (P interaction = .39), and between the type of PRS (P interaction = .81).
Conclusion: We demonstrated in the largest study to date that the use of a PRSCAD allowed us to further refine risk stratification in HeFH. Further studies are needed to evaluate the clinical value of adding the PRSCAD to current risk prediction tools.
期刊介绍:
Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner.
Sections of Journal of clinical lipidology will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.